{"product_id":"quidelortho-bcg-matrix","title":"QuidelOrtho Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where QuidelOrtho’s products really sit—Stars, Cash Cows, Dogs or Question Marks? This preview teases the story; the full BCG Matrix gives you quadrant-by-quadrant placements, data-backed recommendations, and strategic moves you can act on. Buy the complete report for a clear roadmap to allocate capital, prioritize R\u0026amp;D, and present with confidence—delivered in ready-to-use Word and Excel formats. Purchase now and skip the guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid POC infectious disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho’s rapid POC respiratory and strep tests sit in a fast‑growing POC infectious disease market that surpassed $35B in 2024, giving the company real share to defend. Healthcare systems demand speed at the bedside, and the company’s broad menu delivers rapid results and clinician adoption. It’s a leadership position but continues to burn cash for placement, distribution, and awareness. Keep fueling it—these franchises can mature into massive cash generators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized cardiometabolic POC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinics and urgent care centers are shifting cardiometabolic testing to the point of care, boosting demand for decentralized solutions. Where QuidelOrtho already has footprint, market share is strong and growth is brisk, driven by faster decision-making and patient convenience. Sustained investment in instrument placements, EHR connectivity, and improved turnaround time is essential to hold the lead and scale—classic Star territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal infectious disease menu expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanding QuidelOrtho test menus into TB, HIV screening and region-specific pathogens targets an addressable population of 10.6 million TB cases and 38.4 million people living with HIV (WHO\/UNAIDS), accelerating growth in developing markets. Leveraging existing sales channels and rapid, simple assays drives share where turnaround time matters; rollout needs field education, regulatory approvals and inventory investment; adoption momentum compounds once tipping points are reached.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital connectivity and analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLabs demand uptime, QC automation, and actionable analytics and will standardize on vendors who deliver; QuidelOrtho can attach software to its installed instruments to win high-share bundles and increase recurring service revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eGrowth is strong but requires continued R\u0026amp;D and scaled customer-success to convert installations into subscription value; invest now to lock in retention and upsell economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTags: uptime, QC automation, analytics\u003c\/li\u003e\n\u003cli\u003e2024 focus: attach software to hardware for recurring revenue\u003c\/li\u003e\n\u003cli\u003eNeed: sustained R\u0026amp;D and customer-success investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSyndromic respiratory at the point of care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSyndromic respiratory at the point of care: multiplex panels (flu\/RSV\/COVID and other pathogens) are carving a fast-growth niche; as of 2024 many platforms deliver sub-30-minute results and simultaneous detection of 4+ targets. Where QuidelOrtho leads on ease-of-use and turnaround, per-test ASPs skew high; education and reimbursement remain barriers to faster adoption. Push hard — this can graduate into a Cash Cow as the market matures.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: sub-30-minute POC multiplexes; 4+ targets\u003c\/li\u003e\n\u003cli\u003eStrength: ease-of-use, turnaround, premium ASPs\u003c\/li\u003e\n\u003cli\u003eNeeds: clinician education, payer reimbursement\u003c\/li\u003e\n\u003cli\u003eStrategy: invest to capture maturing market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid POC multiplexes target a \u0026gt;$35B market - sub-30-min results, R\u0026amp;D to monetize growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuidelOrtho’s rapid POC infectious‑disease and cardiometabolic tests sit in a \u0026gt;$35B POC market in 2024, with syndromic multiplexes delivering sub‑30‑minute, 4+ target results and strong ASPs; continued R\u0026amp;D, placements, EHR connectivity and customer‑success investment are required to convert Stars into cash cows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOC market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$35B\u003c\/td\u003e\n\u003ctd\u003eLarge TAM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiplexes\u003c\/td\u003e\n\u003ctd\u003esub‑30 min; 4+ targets\u003c\/td\u003e\n\u003ctd\u003ePremium ASPs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB\/HIV\u003c\/td\u003e\n\u003ctd\u003e10.6M \/ 38.4M\u003c\/td\u003e\n\u003ctd\u003eDeveloping market growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG review of QuidelOrtho products, outlining Stars, Cash Cows, Question Marks and Dogs with strategic recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix pinpointing QuidelOrtho units, easing portfolio decisions for execs; export-ready for PPT or print.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled lab analyzers (chemistry\/immunoassay)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstalled lab analyzers drive sticky reagent pull-through, with the global in vitro diagnostics market about $93 billion in 2024 and clinical chemistry a ~$22 billion segment, so share and recurring margins for QuidelOrtho are strong. Market growth is modest (low-single-digit CAGR), promotion spend light, and service\/reliability sustain utilization and uptime. Focus on milking installed base while optimizing service routes, parts stocking and preventive maintenance to protect margin and pull-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunohematology and transfusion consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlood typing and related reagents are mission-critical, recurring, and mature; WHO reports about 118.5 million blood donations annually, underpinning steady demand. QuidelOrtho holds strong positions across many hospital accounts, converting high-margin recurring sales into cash with low single-digit market growth (≈3% CAGR). Maintain ironclad quality and capture incremental efficiency in manufacturing and supply chain to preserve cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine infectious disease rapid tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoutine Strep A and flu A\/B rapid tests sell steadily season after season, forming a dependable cash engine; QuidelOrtho reported roughly $3.6 billion revenue in FY2024 with the diagnostics\/rapid-test franchise representing about 60% of sales, reflecting meaningful market share in a mature segment. Limited need for heavy promotion means distribution reach and pricing discipline drive margin and free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagents, controls, and calibration bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReagents, controls, and calibration bundles deliver predictable, high-margin recurring revenue tied to installed QuidelOrtho instruments; in FY2024 QuidelOrtho reported $1.57 billion in revenue, with consumables underpinning steady cash flow. Growth is low but dependable, switching costs favor the incumbent; prioritize supply reliability and contracting to protect share—quietly powerful cash generation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring margin: high, instrument-tied\u003c\/li\u003e\n\u003cli\u003eGrowth: low but dependable (FY2024 base)\u003c\/li\u003e\n\u003cli\u003eSwitching costs: favor incumbent\u003c\/li\u003e\n\u003cli\u003eFocus: supply reliability and contracting to protect share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService contracts and uptime guarantees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInstalled QuidelOrtho instruments generate annuity-like service revenue tied to consumables and maintenance; the clinical diagnostics service market remained mature and sticky in 2024 with reported renewal rates above 85% per industry summaries. Optimizing coverage models and scaling remote diagnostics can widen service margins and reduce field costs. Cash Cow 101: recurring, high-margin, low-growth cash generation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base → steady annuity revenue\u003c\/li\u003e\n\u003cli\u003eRenewal rates \u0026gt;85% (2024 industry reports)\u003c\/li\u003e\n\u003cli\u003eRemote diagnostics cut service costs, lift margins\u003c\/li\u003e\n\u003cli\u003eOptimize coverage to monetize installed instruments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled analyzers = \u003cstrong\u003e$1.57B\u003c\/strong\u003e annuity; prioritize service, supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInstalled analyzers and consumables drive high-margin annuity cash: QuidelOrtho FY2024 revenue ≈ $3.6B with consumables\/reagents ≈ $1.57B; global IVD market ≈ $93B (clinical chemistry ~$22B) in 2024. Renewal rates \u0026gt;85%; growth low-single-digit. Prioritize service, supply reliability, and contract capture.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e$1.57B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal IVD\u003c\/td\u003e\n\u003ctd\u003e$93B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eQuidelOrtho BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe QuidelOrtho BCG Matrix you're previewing on this page is the exact file you'll receive after purchase — no watermarks, no placeholders, just the finished, professionally formatted report. Built with market-backed insights and strategic clarity, it arrives ready to download, edit, print, or present. Buy once and get immediate access; the full document will be delivered straight to your inbox with no surprises and no extra steps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163996500345,"sku":"quidelortho-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/quidelortho-bcg-matrix.png?v=1762723936","url":"https:\/\/portersfiveforce.com\/products\/quidelortho-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}